• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国医院药房受控物质转移行为全国调查的见解:加强监测与合规的机遇

Insights from a National Survey on Controlled Substance Diversion Practices in U.S. Hospital Pharmacies: Opportunities for Enhanced Surveillance and Compliance.

作者信息

Bastow Samantha S, Borrelli Eric P, Lucaci Julia D, Nelkin Heather, Graves April, Hays Amanda

机构信息

Department of Medical Affairs, Becton Dickinson and Company, Franklin Lakes, NJ 07417, USA.

Department of Health Economic and Outcomes Research, Becton Dickinson and Company, Franklin Lakes, NJ 07417, USA.

出版信息

Pharmacy (Basel). 2024 Dec 4;12(6):183. doi: 10.3390/pharmacy12060183.

DOI:10.3390/pharmacy12060183
PMID:39728848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11676067/
Abstract

This study explored controlled substance (CS) diversion surveillance practices within hospital pharmacies across the United States. A survey with questions based on published CS diversion risk points was conducted in May 2024. A total of 66 participants from 31 states responded, with 54.5% from single facilities and the remaining from health systems. Most respondents were pharmacy directors, managers, or those in dedicated drug diversion roles. Over 70% have dedicated surveillance teams and use drug diversion software. Results highlight variation in practices, with larger institutions generally showing better compliance. Compliance in procurement and receiving was high for access measures; however, auditing of processes was lower. The lowest procurement compliance was in monitoring periodic automatic replacement (PAR) levels and validating orders with wholesalers. Storage practices showed high compliance in deploying cameras, but low compliance in monitoring them. Dispensing practices had high compliance for restricting CS in automated dispensing cabinets, but low incidence of witness verification during stocking. Waste and disposal practices were well-followed, but training on detecting potential signs of medication tampering was less common. The survey highlights that while strategies to prevent CS diversion exist, their implementation varies. Enhancing monitoring, auditing, and training is essential to strengthen diversion prevention efforts in hospital pharmacies.

摘要

本研究探讨了美国各地医院药房内的管制药品(CS)转移监测做法。2024年5月进行了一项基于已发表的CS转移风险点设置问题的调查。来自31个州的66名参与者做出了回应,其中54.5%来自单一机构,其余来自医疗系统。大多数受访者是药房主任、经理或担任专门药品转移工作的人员。超过70%的受访者拥有专门的监测团队并使用药品转移软件。结果凸显了做法上的差异,较大的机构通常合规性更好。在准入措施方面,采购和接收环节的合规性较高;然而,流程审计的合规性较低。采购合规性最低的是监测定期自动补货(PAR)水平以及与批发商核实订单。储存做法在安装摄像头方面合规性较高,但在监控摄像头方面合规性较低。调配做法在自动调配柜中限制CS方面合规性较高,但在备货期间见证核实的发生率较低。废物和处置做法得到了很好的遵循,但关于检测药品篡改潜在迹象的培训不太常见。该调查强调,虽然存在预防CS转移的策略,但其实施情况各不相同。加强监测、审计和培训对于加强医院药房的转移预防工作至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/67cc92d5e740/pharmacy-12-00183-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/ae87e49539e3/pharmacy-12-00183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/11343ef118d2/pharmacy-12-00183-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/0c899a0b52c0/pharmacy-12-00183-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/f210bb9e03e1/pharmacy-12-00183-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/765196032eb1/pharmacy-12-00183-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/f4ee04b99717/pharmacy-12-00183-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/0bbcc2a8790d/pharmacy-12-00183-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/e7d2238d1912/pharmacy-12-00183-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/1927f2f239f7/pharmacy-12-00183-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/56ec0b86558a/pharmacy-12-00183-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/bad69820046f/pharmacy-12-00183-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/eb37e3bf9d98/pharmacy-12-00183-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/f2a46b4e790c/pharmacy-12-00183-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/7017e2e6651d/pharmacy-12-00183-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/14badfe21713/pharmacy-12-00183-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/a6fa6aa00e5d/pharmacy-12-00183-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/c098f3f2662f/pharmacy-12-00183-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/fe9d0d8ebb17/pharmacy-12-00183-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/c7be635c9b57/pharmacy-12-00183-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/67cc92d5e740/pharmacy-12-00183-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/ae87e49539e3/pharmacy-12-00183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/11343ef118d2/pharmacy-12-00183-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/0c899a0b52c0/pharmacy-12-00183-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/f210bb9e03e1/pharmacy-12-00183-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/765196032eb1/pharmacy-12-00183-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/f4ee04b99717/pharmacy-12-00183-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/0bbcc2a8790d/pharmacy-12-00183-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/e7d2238d1912/pharmacy-12-00183-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/1927f2f239f7/pharmacy-12-00183-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/56ec0b86558a/pharmacy-12-00183-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/bad69820046f/pharmacy-12-00183-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/eb37e3bf9d98/pharmacy-12-00183-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/f2a46b4e790c/pharmacy-12-00183-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/7017e2e6651d/pharmacy-12-00183-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/14badfe21713/pharmacy-12-00183-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/a6fa6aa00e5d/pharmacy-12-00183-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/c098f3f2662f/pharmacy-12-00183-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/fe9d0d8ebb17/pharmacy-12-00183-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/c7be635c9b57/pharmacy-12-00183-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a85e/11676067/67cc92d5e740/pharmacy-12-00183-g020.jpg

相似文献

1
Insights from a National Survey on Controlled Substance Diversion Practices in U.S. Hospital Pharmacies: Opportunities for Enhanced Surveillance and Compliance.美国医院药房受控物质转移行为全国调查的见解:加强监测与合规的机遇
Pharmacy (Basel). 2024 Dec 4;12(6):183. doi: 10.3390/pharmacy12060183.
2
Compliance with recommendations for prevention and detection of controlled-substance diversion in hospitals.遵守医院内管制药物滥用预防和检测建议的情况。
Am J Health Syst Pharm. 2011 Apr 15;68(8):689-94. doi: 10.2146/ajhp100212.
3
National Hospital and Health-System Controlled Substances Drug Diversion Prevention & Surveillance Program Assessment Survey - 2021.2021年国家医院及医疗系统管制药品药物转移预防与监测项目评估调查
Am J Health Syst Pharm. 2024 Feb 8;81(4):137-145. doi: 10.1093/ajhp/zxad222.
4
ASHP national survey of pharmacy practice in hospital settings: Dispensing and administration-2017.美国卫生系统药师协会医院药房实践全国性调查:调配与给药 - 2017年
Am J Health Syst Pharm. 2018 Aug 15;75(16):1203-1226. doi: 10.2146/ajhp180151. Epub 2018 Jun 14.
5
Vulnerabilities for Drug Diversion in the Handling, Data Entry, and Verification Tasks of 2 Inpatient Hospital Pharmacies: Clinical Observations and Healthcare Failure Mode and Effect Analysis.处理、数据录入和验证 2 家住院药房药物滥用漏洞:临床观察和医疗保健失效模式和效果分析。
J Patient Saf. 2022 Jan 1;18(1):e227-e235. doi: 10.1097/PTS.0000000000000744.
6
Controlled substance diversion in health systems: A failure modes and effects analysis for prevention.卫生系统中受控物质的转移:预防的失效模式和影响分析。
Am J Health Syst Pharm. 2019 Jul 18;76(15):1158-1164. doi: 10.1093/ajhp/zxz116.
7
Centralizing a controlled substance compliance and drug diversion prevention program within a multihospital health system.将受控物质合规和药物滥用预防计划集中在一个多医院医疗系统内。
Am J Health Syst Pharm. 2023 Jul 21;80(15):1018-1025. doi: 10.1093/ajhp/zxad093.
8
Controlled Substance Reconciliation Accuracy Improvement Using Near Real-Time Drug Transaction Capture from Automated Dispensing Cabinets.利用自动发药柜的近实时药品交易记录提高管制药品核对准确性
Anesth Analg. 2016 Jun;122(6):1841-55. doi: 10.1213/ANE.0000000000001289.
9
Understanding the social networks that contribute to diversion in hospital inpatient pharmacies: A social network analysis.了解导致医院住院药房药品转移的社会网络:一项社会网络分析。
Explor Res Clin Soc Pharm. 2024 Oct 19;16:100530. doi: 10.1016/j.rcsop.2024.100530. eCollection 2024 Dec.
10
Controlled substances in hospices after patient death: a cross-sectional survey of Ontario hospices.临终关怀机构中患者死亡后的管制药物:安大略省临终关怀机构的横断面调查。
Int J Clin Pharm. 2020 Oct;42(5):1344-1353. doi: 10.1007/s11096-020-01097-y. Epub 2020 Aug 19.

本文引用的文献

1
ASHP National Survey of Pharmacy Practice in Hospital Settings: Operations and Technology - 2023.ASHP 医院药学实践全国调查:运营与技术 - 2023 年。
Am J Health Syst Pharm. 2024 Aug 12;81(16):684-705. doi: 10.1093/ajhp/zxae118.
2
ASHP National Survey of Pharmacy Practice in Hospital Settings: Workforce - 2022.ASHP 医院药学实践全国调查:人员配置-2022 年。
Am J Health Syst Pharm. 2023 Jun 7;80(12):719-741. doi: 10.1093/ajhp/zxad055.
3
ASHP Guidelines on Preventing Diversion of Controlled Substances.美国卫生系统药师协会关于防止管制药品转移的指南。
Am J Health Syst Pharm. 2022 Dec 5;79(24):2279-2306. doi: 10.1093/ajhp/zxac246.
4
Vulnerabilities for Drug Diversion in the Handling, Data Entry, and Verification Tasks of 2 Inpatient Hospital Pharmacies: Clinical Observations and Healthcare Failure Mode and Effect Analysis.处理、数据录入和验证 2 家住院药房药物滥用漏洞:临床观察和医疗保健失效模式和效果分析。
J Patient Saf. 2022 Jan 1;18(1):e227-e235. doi: 10.1097/PTS.0000000000000744.
5
Diversion of Controlled Drugs in Hospitals: A Scoping Review of Contributors and Safeguards.医院中管制药物的转移:对贡献者和保障措施的范围综述。
J Hosp Med. 2019 Jul;14(7):419-428. doi: 10.12788/jhm.3228.
6
Hepatitis C Virus Potentially Transmitted by Opioid Drug Diversion from a Nurse - Washington, August 2017-March 2018.华盛顿州 2017 年 8 月至 2018 年 3 月,护士滥用阿片类药物导致丙型肝炎病毒潜在传播。
MMWR Morb Mortal Wkly Rep. 2019 Apr 26;68(16):374-376. doi: 10.15585/mmwr.mm6816a3.
7
Description and comparison of medication diversion in pharmacies by pharmacists, interns, and pharmacy technicians.药剂师、实习生和药房技术员在药房进行药物转移的描述与比较。
J Am Pharm Assoc (2003). 2018 May-Jun;58(3):275-280. doi: 10.1016/j.japh.2018.02.009. Epub 2018 Mar 27.
8
Outbreaks of infections associated with drug diversion by US health care personnel.美国医护人员与药品挪用相关的感染暴发情况。
Mayo Clin Proc. 2014 Jul;89(7):878-87. doi: 10.1016/j.mayocp.2014.04.007. Epub 2014 Jun 2.
9
Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention.医疗机构内的药品转移,一种多受害者犯罪:转移模式、范围、后果、检测和预防。
Mayo Clin Proc. 2012 Jul;87(7):674-82. doi: 10.1016/j.mayocp.2012.03.013.
10
Compliance with recommendations for prevention and detection of controlled-substance diversion in hospitals.遵守医院内管制药物滥用预防和检测建议的情况。
Am J Health Syst Pharm. 2011 Apr 15;68(8):689-94. doi: 10.2146/ajhp100212.